Bioceltech Therapeutics, Ltd. is a high-tech company which focuses on the development and application of new technology in immunotherapy. It is located in the key planning gathering area of Bio-High-Tech industry -- PKUCare Industrial Park, Zhongguancun Life Science Park, Beijing.
The core technology team consists of many senior immunotherapy experts from the University of Pennsylvania, Harvard University and other famous American immunotherapy centers and enterprises. They have engaged in the research and development, quality control, standardized production and clinical application management of immunotherapy such as CAR-T for nearly 20 years.
The team has cooperated with the Institute Of Hematology, Peking University People's Hospital since 2016 and together we successfully cured a 3-year-old patient with Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) by using HLA-haploidentical allogenic CAR-T cell therapy (T-cells of the patient's relatives).
umor biological therapy is a new approach of tumor therapy with remarkable curative effect, and it is a novel method of autoimmune anticancer treatment.
The inspection and evaluation of immune function are important for clinical guidance and monitoring, either for patients who receiving immunotherapy or for sub-health and normal people who receiving immune cell health care.
Recently，immunosenscence is becoming one of the hot topic in the research field of basic immunology and immunotherapy
Stem cells, with the potential of self-renewal and multi-directional differentiation, are the original cells of the organism. They can form various tissues and organs of human body. Under certain conditions, it can differentiate into many functional cells、tissue and organs. It is called “Universal cell” in medical field.
（CAR-T technology is a developed adoptive cell therapy in recent years, and it is recognized as a unique way to completely conquer human cancers. In August 2011, the American Journal of Bio-Translational Medicine and the New England Journal of Medicine reported that professor Carl H. June, who is a gene therapist at the University of Pennsylvania, had cured two patients with Advanced Chronic Lymphoblastic Leukemia (CLL) by using a modified autologous T-cell (CAR-T).
异体CAR-T“北京方案”再传佳音！白血病患儿治愈已3年  |
| 许中伟教授与原领导Carl June教授及其课题组共同发表CAR-T综述文章 |
| 许中伟博士应聘为北京大学免疫学系全球共探路 |
| Dr.Michael 出访贝斯特公司官网公司并与首席科学家许中伟教授参加“新生物制药时代 |
| 球共探路：贝斯特公司官网CEO姚毅博士应邀参加第九届财新峰会 |
| 贝斯特公司官网首席科学家许中伟教授、姚毅博士应邀参加“2018医学免疫与临床应用高峰论坛” |
| 贝斯特公司官网首席科学家许中伟教授受邀参加第三届北京国际医学工程大会暨国际医药人工智能大会 |
| 贝斯特公司官网再添虎将---FDA姚毅博士担任公司首席医学总监 |
| 公司开展细胞药物GMP的实施研讨活动 |
